Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma

Benedek Gyöngyösi, Éva Végh, Balázs Járay, Eszter Székely, Matteo Fassan, G. Bodoky, Z. Schaff, András Kiss

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA was obtained from all the considered samples (mean 10.8 ± 9.3 μg, range 0.2-32.2 μg). Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment of expected survival rates for patients under sorafenib treatment.

Original languageEnglish
Pages (from-to)547-555
Number of pages9
JournalJournal of Histochemistry and Cytochemistry
Volume62
Issue number8
DOIs
Publication statusPublished - 2014

Fingerprint

MicroRNAs
Hepatocellular Carcinoma
RNA
Survival
Survival Analysis
Fine Needle Biopsy
Disease-Free Survival
Therapeutics
Software
Survival Rate
sorafenib
Polymerase Chain Reaction
Neoplasms

Keywords

  • FNAB
  • hepatocellular carcinoma
  • microRNA
  • sorafenib
  • survival

ASJC Scopus subject areas

  • Anatomy
  • Histology

Cite this

Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. / Gyöngyösi, Benedek; Végh, Éva; Járay, Balázs; Székely, Eszter; Fassan, Matteo; Bodoky, G.; Schaff, Z.; Kiss, András.

In: Journal of Histochemistry and Cytochemistry, Vol. 62, No. 8, 2014, p. 547-555.

Research output: Contribution to journalArticle

Gyöngyösi, Benedek ; Végh, Éva ; Járay, Balázs ; Székely, Eszter ; Fassan, Matteo ; Bodoky, G. ; Schaff, Z. ; Kiss, András. / Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma. In: Journal of Histochemistry and Cytochemistry. 2014 ; Vol. 62, No. 8. pp. 547-555.
@article{90472fdb045c4ea39dd0c15bcc5282af,
title = "Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma",
abstract = "Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA was obtained from all the considered samples (mean 10.8 ± 9.3 μg, range 0.2-32.2 μg). Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment of expected survival rates for patients under sorafenib treatment.",
keywords = "FNAB, hepatocellular carcinoma, microRNA, sorafenib, survival",
author = "Benedek Gy{\"o}ngy{\"o}si and {\'E}va V{\'e}gh and Bal{\'a}zs J{\'a}ray and Eszter Sz{\'e}kely and Matteo Fassan and G. Bodoky and Z. Schaff and Andr{\'a}s Kiss",
year = "2014",
doi = "10.1369/0022155414537277",
language = "English",
volume = "62",
pages = "547--555",
journal = "Journal of Histochemistry and Cytochemistry",
issn = "0022-1554",
publisher = "Histochemical Society Inc.",
number = "8",

}

TY - JOUR

T1 - Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma

AU - Gyöngyösi, Benedek

AU - Végh, Éva

AU - Járay, Balázs

AU - Székely, Eszter

AU - Fassan, Matteo

AU - Bodoky, G.

AU - Schaff, Z.

AU - Kiss, András

PY - 2014

Y1 - 2014

N2 - Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA was obtained from all the considered samples (mean 10.8 ± 9.3 μg, range 0.2-32.2 μg). Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment of expected survival rates for patients under sorafenib treatment.

AB - Sorafenib represents the first effective targeted therapy for advanced stage hepatocellular carcinoma (HCC); however, adequate patient stratification regarding sorafenib-responsiveness is still missing. Our aim was to analyse the association between the pretreatment microRNA profile of HCC and patient survival under sorafenib treatment. Total RNA was extracted from diagnostic fine-needle aspiration biopsy (FNAB) cytological smears of 20 advanced stage HCC patients collected between June 2008 and July 2012. All patients underwent sorafenib administration after FNA. Clinicopathological and survival data were recorded. Fourteen frequently deregulated miRNAs in HCC (miR-17-5p, miR-18a, miR-21, miR-34a, miR-122, miR-195, miR-210, miR-214, miR-221, miR-222, miR-223, miR-224, miR-140, miR-328) were tested by qRT-PCR. NormFinder software was used to select proper miR (mir-140) as a reference. Satisfactory amount of total RNA was obtained from all the considered samples (mean 10.8 ± 9.3 μg, range 0.2-32.2 μg). Among the analysed miRNAs, high miR-214 expression was associated with smaller tumor size (p=0.019), whereas high miR-17-5p expression correlated with better Eastern Cooperative Oncology Group performance status (p=0.003). The survival analysis revealed that high miR-224 expression was associated with increased progression-free and overall survival (PFS p=0.029; OS p=0.012). Pretreatment microRNA profiling, especially miR-224 expression, might serve as an ancillary tool for the better assessment of expected survival rates for patients under sorafenib treatment.

KW - FNAB

KW - hepatocellular carcinoma

KW - microRNA

KW - sorafenib

KW - survival

UR - http://www.scopus.com/inward/record.url?scp=84904987193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904987193&partnerID=8YFLogxK

U2 - 10.1369/0022155414537277

DO - 10.1369/0022155414537277

M3 - Article

C2 - 24804874

AN - SCOPUS:84904987193

VL - 62

SP - 547

EP - 555

JO - Journal of Histochemistry and Cytochemistry

JF - Journal of Histochemistry and Cytochemistry

SN - 0022-1554

IS - 8

ER -